Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients
Bluejay Diagnostics released baseline data from its SYMON-II study, evaluating the IL-6 biomarker for mortality risk in sepsis patients.
Stocks · News reference
8-K filing — Bluejay Diagnostics, Inc. (BJDX)
Filed: 2026-10-06 AccNo: 0001213900-26-106999 Size: 252 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Bluejay Diagnostics Reports SYMON-II Baseline Data Showing Diverse Critically Ill Sepsis Population And Meaningful Mortality Events Supporting IL-6 Evaluation For 28-Day Mortality Risk
SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Toward Regulatory SubmissionACTON, MA / ACCESS Newswire / October 6, 2026 / Bluejay Diagnostics, Inc.
Bluejay Diagnostics shares are trading higher after the company announced a strategic partnership with Lovell Government Services to support the introduction of its products into the federal healthcare market.